EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.651
https://www.valueinhealthjournal.com/article/S1098-3015(23)03781-6/fulltext
Section Title :
Section Order :
10133
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03781-6&doi=10.1016/j.jval.2023.09.651